Australia's CSL partners with VarmX on first-in- class coagulation treatment in $2.2 B deal

Singapore, Sept. 17 -- Australia's CSL Limited has entered into an agreement with privately held Dutch biotech company, VarmX BV, to develop a new treatment to restore blood coagulation in patients taking a FXa inhibitor.

Published by HT Digital Content Services with permission from BioSpectrum Asia....